NFE2L2 and asthma: Taken together, our results indicate that endogenous Nrf2 response is insufficient to counteract CuONP-driven asthma exacerbation, whereas pharmacological or genetic augmentation of Nrf2 signaling may constitute a viable strategy to alleviate nanoparticle-induced respiratory injury.